|
humans |
247 |
|
male |
210 |
|
female |
204 |
|
hepatocellular carcinoma |
172 |
|
adult |
171 |
|
middle aged |
169 |
|
aged |
144 |
|
prognosis |
118 |
|
animals |
112 |
|
medical sciences |
110 |
|
recurrence |
99 |
|
chinese |
92 |
|
treatment outcome |
90 |
|
aged, 80 and over |
87 |
|
covid-19 |
86 |
|
survival |
82 |
|
liver transplantation |
80 |
|
adolescent |
78 |
|
cell line, tumor |
77 |
|
hong kong |
73 |
|
surgery |
73 |
|
apoptosis |
71 |
|
metastasis |
69 |
|
mice |
69 |
|
cell proliferation |
67 |
|
biomarker |
66 |
|
hong kong - epidemiology |
66 |
|
reverse transcriptase polymerase chain reaction |
65 |
|
time factors |
64 |
|
survival analysis |
62 |
|
gene expression regulation, neoplastic |
61 |
|
immunohistochemistry |
60 |
|
nasopharyngeal carcinoma |
60 |
|
colorectal cancer |
58 |
|
prospective studies |
56 |
|
retrospective studies |
56 |
|
follow-up studies |
54 |
|
hcc |
54 |
|
children |
52 |
|
molecular sequence data |
52 |
|
neoplasm staging |
52 |
|
cancer |
50 |
|
sars-cov-2 |
50 |
|
gastric cancer |
49 |
|
mutation |
49 |
|
quality of life |
49 |
|
base sequence |
48 |
|
survival rate |
48 |
|
oncology |
47 |
|
child |
46 |
|
genetic predisposition to disease |
46 |
|
risk factors |
46 |
|
up-regulation |
46 |
|
disease progression |
45 |
|
liver cancer |
45 |
|
china |
44 |
|
dna methylation |
44 |
|
epidemiology |
44 |
|
gene expression |
44 |
|
infant |
44 |
|
age factors |
43 |
|
promoter regions, genetic |
43 |
|
rats |
43 |
|
breast cancer |
42 |
|
child, preschool |
42 |
|
cohort studies |
42 |
|
inflammation |
42 |
|
blotting, western |
41 |
|
gastroenterology |
41 |
|
gene expression profiling |
41 |
|
mice, nude |
41 |
|
radiotherapy |
41 |
|
down-regulation |
40 |
|
transfection |
40 |
|
asian continental ancestry group - genetics |
39 |
|
hepatectomy |
39 |
|
chemotherapy |
38 |
|
esophageal squamous cell carcinoma |
38 |
|
mortality |
38 |
|
neoplasm invasiveness |
38 |
|
postoperative complications |
38 |
|
case-control studies |
37 |
|
enzyme-linked immunosorbent assay |
37 |
|
immunotherapy |
37 |
|
outcome |
37 |
|
tumor cells, cultured |
37 |
|
cell movement |
36 |
|
esophageal cancer |
36 |
|
risk factor |
36 |
|
case report |
35 |
|
carcinoma |
34 |
|
combined modality therapy |
34 |
|
disease-free survival |
34 |
|
tomography, x-ray computed |
34 |
|
asia |
33 |
|
biliary atresia |
33 |
|
diagnosis |
33 |
|
angiogenesis |
32 |
|
biomarkers |
32 |
|
controlled study |
32 |
|
incidence |
32 |
|
promoter regions, genetic - genetics |
32 |
|
proteomics |
32 |
|
risk assessment |
32 |
|
rna, messenger - metabolism |
32 |
|
squamous cell carcinoma |
32 |
|
cirrhosis |
31 |
|
gene silencing |
31 |
|
laparoscopy |
31 |
|
liver |
31 |
|
lymphatic metastasis |
31 |
|
multivariate analysis |
31 |
|
signal transduction |
31 |
|
human |
30 |
|
liver transplant |
30 |
|
microrna |
30 |
|
polymerase chain reaction |
30 |
|
asian |
29 |
|
cytokines |
29 |
|
dna mutational analysis |
29 |
|
prevalence |
29 |
|
rats, sprague-dawley |
29 |
|
alleles |
28 |
|
amino acid sequence |
28 |
|
cell differentiation |
28 |
|
chi-square distribution |
28 |
|
morbidity |
28 |
|
neoplasm transplantation |
28 |
|
oligonucleotide array sequence analysis |
28 |
|
p53 |
28 |
|
proliferation |
28 |
|
transcription, genetic |
28 |
|
vitamin d |
28 |
|
cisplatin |
27 |
|
deep learning |
27 |
|
dose-response relationship, drug |
27 |
|
emt |
27 |
|
gastroenterology medical sciences |
27 |
|
hepatitis b virus |
27 |
|
hirschsprung disease |
27 |
|
outcomes |
27 |
|
transarterial chemoembolization |
27 |
|
cell proliferation - drug effects |
26 |
|
chemoresistance |
26 |
|
coronavirus |
26 |
|
e-cadherin |
26 |
|
neoadjuvant therapy |
26 |
|
sars-cov |
26 |
|
asian continental ancestry group |
25 |
|
complications |
25 |
|
epithelial-mesenchymal transition |
25 |
|
genome-wide association study |
25 |
|
genotype |
25 |
|
living donors |
25 |
|
rna, messenger - genetics - metabolism |
25 |
|
wound healing |
25 |
|
cytology and histology |
24 |
|
endoscopy |
24 |
|
helicobacter pylori |
24 |
|
ischemic stroke |
24 |
|
liver fibrosis |
24 |
|
mice, inbred balb c |
24 |
|
neoplasm metastasis |
24 |
|
polymorphism, single nucleotide - genetics |
24 |
|
sensitivity and specificity |
24 |
|
targeted therapy |
24 |
|
transplantation, heterologous |
24 |
|
treatment |
24 |
|
whole-exome sequencing |
24 |
|
young adult |
24 |
|
acute disease |
23 |
|
animal tissue |
23 |
|
elderly |
23 |
|
fatal outcome |
23 |
|
genetic association |
23 |
|
hepatitis b |
23 |
|
homeodomain proteins - genetics - metabolism |
23 |
|
infant, newborn |
23 |
|
long-term outcome |
23 |
|
oncology medical sciences |
23 |
|
polymorphism, single nucleotide |
23 |
|
radiology and nuclear medicine pharmacy and pharmacology biology |
23 |
|
reproducibility of results |
23 |
|
ret |
23 |
|
single nucleotide polymorphism |
23 |
|
sorafenib |
23 |
|
type 2 diabetes |
23 |
|
copy number variation |
22 |
|
glycolysis |
22 |
|
graft survival |
22 |
|
hypoxia |
22 |
|
magnetic resonance imaging |
22 |
|
medicine & public health |
22 |
|
mri |
22 |
|
phosphorylation |
22 |
|
transcription factors - genetics |
22 |
|
β-catenin |
22 |
|
cell line |
21 |
|
double-blind method |
21 |
|
drug therapy, combination |
21 |
|
extracellular vesicles |
21 |
|
gene expression regulation |
21 |
|
gene mutation |
21 |
|
general surgery |
21 |
|
genes, tumor suppressor |
21 |
|
invasion |
21 |
|
length of stay |
21 |
|
nafld |
21 |
|
nf-κb |
21 |
|
pathogenesis |
21 |
|
stents |
21 |
|
thyroidectomy |
21 |
|
tumor markers, biological - blood |
21 |
|
analysis of variance |
20 |
|
atrial fibrillation |
20 |
|
biopsy |
20 |
|
cancer staging |
20 |
|
cancer stem cell |
20 |
|
chemicals and cas registry numbers |
20 |
|
computed tomography |
20 |
|
disease models, animal |
20 |
|
escc |
20 |
|
immunosuppression |
20 |
|
liver cirrhosis |
20 |
|
methylation |
20 |
|
phenotype |
20 |
|
polymorphism, genetic |
20 |
|
predictive value of tests |
20 |
|
prognostic factors |
20 |
|
radiofrequency ablation |
20 |
|
reoperation |
20 |
|
tumor recurrence |
20 |
|
artificial intelligence |
19 |
|
cancer stemness |
19 |
|
china - ethnology |
19 |
|
colon cancer |
19 |
|
dna primers |
19 |
|
esophagectomy |
19 |
|
gene frequency |
19 |
|
head and neck cancer |
19 |
|
hepatectomy - methods |
19 |
|
immunosuppressive agents - therapeutic use |
19 |
|
liver neoplasms - metabolism - pathology |
19 |
|
liver resection |
19 |
|
microsatellite repeats |
19 |
|
migration |
19 |
|
nuclear proteins - genetics - metabolism |
19 |
|
tumorigenesis |
19 |
|
adolescents |
18 |
|
advanced hepatocellular carcinoma |
18 |
|
animal experiment |
18 |
|
apoptosis - drug effects |
18 |
|
blood transfusion |
18 |
|
body mass index |
18 |
|
carcinoma, hepatocellular - metabolism - pathology |
18 |
|
carcinoma, hepatocellular - mortality - pathology - surgery |
18 |
|
choledochal cyst |
18 |
|
chronic disease |
18 |
|
esophageal neoplasms - genetics - metabolism - pathology |
18 |
|
flow cytometry |
18 |
|
gene expression regulation, neoplastic - genetics |
18 |
|
liver metastasis |
18 |
|
liver neoplasms - genetics - metabolism - pathology |
18 |
|
liver transplantation - methods |
18 |
|
lymph node metastasis |
18 |
|
major clinical study |
18 |
|
malignancy |
18 |
|
microarray |
18 |
|
mutation - genetics |
18 |
|
neoplasm recurrence, local - surgery |
18 |
|
portal vein |
18 |
|
registries |
18 |
|
resection |
18 |
|
sex factors |
18 |
|
syndrome |
18 |
|
transcription factors - genetics - metabolism |
18 |
|
tumor microenvironment |
18 |
|
tumor suppressor |
18 |
|
tumor suppressor gene |
18 |
|
vascular surgery |
18 |
|
antiviral agents - therapeutic use |
17 |
|
bile duct atresia |
17 |
|
brachytherapy |
17 |
|
cadaver |
17 |
|
cancer stem cells |
17 |
|
carcinoma, squamous cell - genetics - metabolism - pathology |
17 |
|
cell adhesion molecules - genetics |
17 |
|
cells, cultured |
17 |
|
cholangiocarcinoma |
17 |
|
cricetinae |
17 |
|
enzyme inhibitors - pharmacology |
17 |
|
genetic susceptibility |
17 |
|
hirschsprung disease - genetics |
17 |
|
in situ hybridization, fluorescence |
17 |
|
liver neoplasms - mortality - pathology - surgery |
17 |
|
liver transplantation - adverse effects |
17 |
|
living donor liver transplant |
17 |
|
machine learning |
17 |
|
meta-analysis |
17 |
|
next-generation sequencing |
17 |
|
nf-κb signaling |
17 |
|
palliative care |
17 |
|
patient selection |
17 |
|
pin1 |
17 |
|
postoperative complications - epidemiology |
17 |
|
probability |
17 |
|
replication |
17 |
|
rna, messenger - genetics |
17 |
|
therapeutics |
17 |
|
transcription factors - metabolism |
17 |
|
tricuspid annuloplasty |
17 |
|
two-hybrid system techniques |
17 |
|
ultrasonography |
17 |
|
antigens, cd - genetics |
16 |
|
antineoplastic agents - therapeutic use |
16 |
|
association |
16 |
|
brain |
16 |
|
cardiac surgery |
16 |
|
child psychosocial problems |
16 |
|
cholangitis |
16 |
|
chromosome mapping |
16 |
|
cytoskeletal proteins - genetics |
16 |
|
diagnosis, differential |
16 |
|
gist |
16 |
|
healthcare workers |
16 |
|
hepatitis |
16 |
|
hepatocellular carcinoma (hcc) |
16 |
|
hirschsprung's disease |
16 |
|
home confinement |
16 |
|
hospital policies |
16 |
|
immunoenzyme techniques |
16 |
|
immunoglobulin |
16 |
|
liver neoplasms - genetics |
16 |
|
mutations |
16 |
|
oral cancer |
16 |
|
perceived stress |
16 |
|
pet/ct |
16 |
|
pregnancy |
16 |
|
psychological wellbeing |
16 |
|
school closure |
16 |
|
sequence analysis, dna |
16 |
|
severity of illness index |
16 |
|
statistics, nonparametric |
16 |
|
surveillance |
16 |
|
survivorship |
16 |
|
tandem repeat sequences |
16 |
|
thoracic surgery |
16 |
|
thyroid cancer |
16 |
|
transplantation |
16 |
|
abdominal surgery |
15 |
|
adiponectin |
15 |
|
anastomosis, surgical |
15 |
|
animal cell |
15 |
|
anorectal malformation |
15 |
|
anosmia |
15 |
|
body weight |
15 |
|
cancer survival |
15 |
|
carcinoma, hepatocellular - genetics |
15 |
|
carcinoma, hepatocellular - genetics - metabolism - pathology |
15 |
|
carcinoma, hepatocellular - mortality - surgery |
15 |
|
carrier proteins - metabolism |
15 |
|
cell transformation, neoplastic - genetics - metabolism |
15 |
|
chromosome aberrations |
15 |
|
complication |
15 |
|
coronary artery disease |
15 |
|
dna-binding proteins - genetics |
15 |
|
emergencies |
15 |
|
enteric nervous system |
15 |
|
fibrosis |
15 |
|
gene identification |
15 |
|
gene locus |
15 |
|
gene therapy |
15 |
|
hepatitis b virus - genetics |
15 |
|
hepatitis b, chronic - complications |
15 |
|
laparoscopic liver resection |
15 |
|
liver disease |
15 |
|
liver failure |
15 |
|
liver neoplasms - mortality - surgery |
15 |
|
liver neoplasms - pathology - surgery |
15 |
|
nasopharyngeal neoplasms - genetics - metabolism - pathology |
15 |
|
neoplasm proteins - genetics |
15 |
|
neuregulin-1 - genetics |
15 |
|
nidogen 1 |
15 |
|
oesophageal cancer |
15 |
|
oesophageal squamous cell carcinoma |
15 |
|
olfactory dysfunction |
15 |
|
priority journal |
15 |
|
proto-oncogene proteins - genetics |
15 |
|
rectal cancer |
15 |
|
reference values |
15 |
|
salvage therapy |
15 |
|
signal transduction - genetics |
15 |
|
therapeutic target |
15 |
|
abdominal pain |
14 |
|
adjuvant chemotherapy |
14 |
|
algorithms |
14 |
|
antineoplastic combined chemotherapy protocols - therapeutic use |
14 |
|
beta catenin |
14 |
|
bridging therapy |
14 |
|
carcinoma, hepatocellular - genetics - metabolism |
14 |
|
carcinoma, squamous cell - genetics - pathology |
14 |
|
cell invasion |
14 |
|
chemoradiotherapy |
14 |
|
coronavirus disease 2019 |
14 |
|
cytoplasm - metabolism |
14 |
|
differentiation |
14 |
|
hepatic resection |
14 |
|
hospital mortality |
14 |
|
immune activation |
14 |
|
intestine |
14 |
|
intraoperative complications - epidemiology |
14 |
|
kaplan-meier estimate |
14 |
|
liver - metabolism |
14 |
|
liver - pathology |
14 |
|
liver function tests |
14 |
|
minimally invasive surgery |
14 |
|
nasopharyngectomy |
14 |
|
neutralizing antibody |
14 |
|
nucleic acid hybridization |
14 |
|
obesity |
14 |
|
pathogenicity |
14 |
|
peptidyl-prolyl-isomerase |
14 |
|
prognostic marker |
14 |
|
proportional hazards models |
14 |
|
recurrent nasopharyngeal carcinoma |
14 |
|
review |
14 |
|
rna interference |
14 |
|
sars |
14 |
|
signal transduction - physiology |
14 |
|
stomach neoplasms - genetics |
14 |
|
tumor markers, biological - analysis |
14 |
|
tumor suppressor protein p53 - metabolism |
14 |
|
vegf |
14 |
|
ablation |
13 |
|
advanced hcc |
13 |
|
akt |
13 |
|
allergology and immunology |
13 |
|
antineoplastic agents - pharmacology |
13 |
|
cadherins - metabolism |
13 |
|
cancer invasion |
13 |
|
cancer susceptibility genes |
13 |
|
cell division |
13 |
|
cell nucleus - metabolism |
13 |
|
child-pugh a |
13 |
|
chromosome 10q |
13 |
|
chromosome deletion |
13 |
|
cyclin-dependent kinase inhibitor p16 - genetics - metabolism |
13 |
|
cyclooxygenase-2 |
13 |
|
dna |
13 |
|
early-age onset |
13 |
|
endovascular |
13 |
|
enzyme activation |
13 |
|
epstein-barr virus |
13 |
|
esophageal squamous cell carcinoma (escc) |
13 |
|
fluorescent antibody technique |
13 |
|
follow up |
13 |
|
gene function |
13 |
|
genetic predisposition |
13 |
|
glioblastoma |
13 |
|
gwas |
13 |
|
heterogeneity |
13 |
|
hong kong chinese |
13 |
|
hypermethylation |
13 |
|
intercellular communication |
13 |
|
intracerebral hemorrhage |
13 |
|
l-lactate dehydrogenase - blood |
13 |
|
liver neoplasms - genetics - metabolism |
13 |
|
liver transplantation - immunology |
13 |
|
local recurrence |
13 |
|
loss of heterozygosity |
13 |
|
lymphocyte subsets |
13 |
|
membrane proteins - genetics - metabolism |
13 |
|
micrornas - genetics |
13 |
|
molecular biology |
13 |
|
mst1r |
13 |
|
neck dissection |
13 |
|
neoplasm proteins - genetics - metabolism |
13 |
|
neoplasm recurrence, local |
13 |
|
polymorphism |
13 |
|
postoperative care |
13 |
|
prevention |
13 |
|
rna, messenger - analysis |
13 |
|
staging |
13 |
|
stomach neoplasms - genetics - pathology |
13 |
|
thoracoscopy |
13 |
|
tissue array analysis |
13 |
|
tissue donors |
13 |
|
trans-activators |
13 |
|
tumor markers, biological - genetics |
13 |
|
tumor markers, biological - genetics - metabolism |
13 |
|
tumor-initiating cells |
13 |
|
type 2 diabetes mellitus |
13 |
|
validity |
13 |
|
vascular surgical procedures - methods |
13 |
|
acute hepatitis |
12 |
|
adverse outcome |
12 |
|
alpha-fetoprotein |
12 |
|
ampk |
12 |
|
aortic aneurysm |
12 |
|
apobec-mediated signature |
12 |
|
arginine methylation |
12 |
|
autophagy |
12 |
|
berberine |
12 |
|
bile ducts - surgery |
12 |
|
bronchiectasis |
12 |
|
cancer cell culture |
12 |
|
cancer metastasis |
12 |
|
cancer recurrence |
12 |
|
capecitabine |
12 |
|
carcinoma, hepatocellular - surgery |
12 |
|
carcinoma, squamous cell - genetics |
12 |
|
carrier proteins - genetics |
12 |
|
carrier state |
12 |
|
cell transformation, neoplastic - genetics |
12 |
|
chemotherapy, adjuvant |
12 |
|
chromosome aberration |
12 |
|
chronic obstructive lung disease |
12 |
|
convalescence |
12 |
|
curcumin |
12 |
|
cyclin d1 - genetics |
12 |
|
dna-binding proteins - metabolism |
12 |
|
enzyme inhibitors - therapeutic use |
12 |
|
ephrin-a2 - genetics |
12 |
|
epigenetics |
12 |
|
esophageal carcinoma |
12 |
|
gene expression regulation - physiology |
12 |
|
gene expression regulation, neoplastic - drug effects |
12 |
|
gwa |
12 |
|
heme oxygenase-1 |
12 |
|
hepaticojejunostomy |
12 |
|
hepatitis b - complications |
12 |
|
homozygote |
12 |
|
human tissue |
12 |
|
indocyanine green |
12 |
|
inguinal hernia |
12 |
|
karyotyping |
12 |
|
laparoscopic |
12 |
|
laparoscopic resection |
12 |
|
liver - metabolism - pathology |
12 |
|
liver diseases - surgery |
12 |
|
liver neoplasms |
12 |
|
liver neoplasms - surgery |
12 |
|
living donor |
12 |
|
logistic models |
12 |
|
lupus erythematosus, systemic - genetics |
12 |
|
management |
12 |
|
meld |
12 |
|
mendelian randomization |
12 |
|
mice, transgenic |
12 |
|
micrornas - genetics - metabolism |
12 |
|
microsatellite repeats - genetics |
12 |
|
mirna |
12 |
|
model for end-stage liver disease |
12 |
|
mtor |
12 |
|
myocardial infarction |
12 |
|
nasopharyngeal cancer |
12 |
|
nasopharyngeal carcinoma (npc) |
12 |
|
nasopharyngeal neoplasms - genetics |
12 |
|
neuroblastoma |
12 |
|
oncogene proteins - genetics |
12 |
|
organ size |
12 |
|
overall survival |
12 |
|
oxidative stress |
12 |
|
pediatric liver transplantation |
12 |
|
postoperative complications - prevention & control |
12 |
|
preoperative care |
12 |
|
promoter hypermethylation |
12 |
|
questionnaires |
12 |
|
receptor protein-tyrosine kinases - genetics - metabolism |
12 |
|
recurrent laryngeal nerve |
12 |
|
reliability |
12 |
|
responsiveness |
12 |
|
reverse transcriptase inhibitors - therapeutic use |
12 |
|
safety |
12 |
|
sars-cov-2 rbd igg |
12 |
|
secondary prevention |
12 |
|
silver nanoparticles |
12 |
|
sle |
12 |
|
somatic mutation landscape |
12 |
|
species index: animalia |
12 |
|
stress |
12 |
|
systematic review |
12 |
|
t cell response |
12 |
|
thrombectomy |
12 |
|
thyroiditis |
12 |
|
tissue distribution |
12 |
|
tissue microarray |
12 |
|
transcriptional activation |
12 |
|
tumor marker |
12 |
|
tumor necrosis factor-alpha - genetics - metabolism |
12 |
|
tumor stem cell assay |
12 |
|
tumor suppressor protein p53 - genetics - metabolism |
12 |
|
uhrf1bp1 |
12 |
|
vascular endothelial growth factor |
12 |
|
wnt signaling pathway |
12 |
|
abdominal aortic aneurysm |
11 |
|
acute flare |
11 |
|
acute-on-chronic liver failure |
11 |
|
adaptor proteins, signal transducing - genetics - metabolism |
11 |
|
afp |
11 |
|
alpps |
11 |
|
aneurysm |
11 |
|
animal model |
11 |
|
anti-bacterial agents - therapeutic use |
11 |
|
antigens, cd3 - genetics |
11 |
|
anxiety |
11 |
|
apoptosis - genetics |
11 |
|
bat |
11 |
|
biological markers - blood |
11 |
|
blood loss, surgical |
11 |
|
blood vessel prosthesis implantation |
11 |
|
cadherins - genetics - metabolism |
11 |
|
carcinoma, hepatocellular - enzymology - pathology |
11 |
|
carcinoma, hepatocellular - etiology - genetics - metabolism |
11 |
|
carcinoma, hepatocellular - genetics - metabolism - pathology - virology |
11 |
|
carcinoma, hepatocellular - mortality - therapy |
11 |
|
catheter ablation |
11 |
|
cd247 |
11 |
|
cell adhesion molecules - genetics - metabolism |
11 |
|
cell cycle |
11 |
|
cell migration |
11 |
|
cell movement - drug effects |
11 |
|
cell transformation, neoplastic |
11 |
|
cercopithecus aethiops |
11 |
|
chemoprevention |
11 |
|
cho cells - virology |
11 |
|
confidence intervals |
11 |
|
cos cells |
11 |
|
cox-2 |
11 |
|
cricetulus |
11 |
|
cross-sectional studies |
11 |
|
cyclin d1 - biosynthesis - genetics |
11 |
|
decompensation |
11 |
|
diagnosis and prognosis |
11 |
|
education |
11 |
|
ethnic group |
11 |
|
feces analysis |
11 |
|
gastrointestinal bleeding |
11 |
|
gene amplification |
11 |
|
gene mapping |
11 |
|
genes |
11 |
|
genes, p53 |
11 |
|
hepatitis b infection |
11 |
|
hepatoblastoma |
11 |
|
hernia |
11 |
|
high-intensity focused ultrasound |
11 |
|
homeodomain proteins - genetics |
11 |
|
hoxb5 |
11 |
|
immunoprecipitation |
11 |
|
immunosuppressive agents - pharmacology |
11 |
|
in situ hybridization |
11 |
|
inhibitor of differentiation protein 1 |
11 |
|
intestine, small - physiology |
11 |
|
kw034 - copy number/structural variation |
11 |
|
lamivudine - therapeutic use |
11 |
|
laparoscopic surgery |
11 |
|
lectins, c-type - genetics - metabolism |
11 |
|
liver neoplasms - enzymology - pathology |
11 |
|
liver neoplasms - genetics - metabolism - pathology - virology |
11 |
|
liver neoplasms - mortality - therapy |
11 |
|
liver transplantation - statistics & numerical data |
11 |
|
living donor liver transplantation |
11 |
|
lung - physiology - virology |
11 |
|
lupus erythematosus, systemic - genetics - immunology |
11 |
|
macrophage |
11 |
|
metastases |
11 |
|
microscopy, electron |
11 |
|
neural crest |
11 |
|
nidogen-2 (nid2) |
11 |
|
non-coding rna |
11 |
|
nucleotide sequence |
11 |
|
oral leukoplakia |
11 |
|
oral lichenoid lesions |
11 |
|
organoid |
11 |
|
paraganglioma |
11 |
|
pediatric |
11 |
|
peptidylprolyl isomerase - biosynthesis - genetics |
11 |
|
peritoneal dialysis |
11 |
|
pre‐metastatic niche |
11 |
|
proteasome endopeptidase complex - metabolism |
11 |
|
pten |
11 |
|
rats, inbred lew |
11 |
|
receptors, cell surface - genetics - metabolism |
11 |
|
repressor proteins |
11 |
|
sars coronavirus |
11 |
|
sars virus - isolation and purification - pathogenicity |
11 |
|
sars virus - metabolism - pathogenicity |
11 |
|
severe acute respiratory syndrome - epidemiology - genetics |
11 |
|
spectrometry, mass, matrix-assisted laser desorption-ionization |
11 |
|
stomach neoplasms - genetics - metabolism |
11 |
|
survival outcomes |
11 |
|
systemic lupus erythematosus |
11 |
|
thyroid function tests |
11 |
|
thyroid gland |
11 |
|
tissue donors - supply and distribution |
11 |
|
trans-activators - genetics |
11 |
|
tumor necrosis factor receptor 1 |
11 |
|
tumor suppressor proteins - genetics - metabolism |
11 |
|
vaccination |
11 |
|
vero cells - virology |
11 |
|
whole exome sequencing |
11 |
|
wound healing - drug effects |
11 |
|
xenograft model antitumor assays |
11 |
|
actins - metabolism |
10 |
|
adeno-associated virus |
10 |
|
adipocyte |
10 |
|
adjuvant therapy |
10 |
|
advanced cancer |
10 |
|
angioplasty |
10 |
|
antigens, cd - genetics - metabolism |
10 |
|
arhgap fusions |
10 |
|
b-type natriuretic peptide |
10 |
|
bevacizumab |
10 |
|
biliary anastomotic stricture |
10 |
|
biliary obstruction |
10 |
|
biobank |
10 |
|
brca1 protein - genetics |
10 |
|
cadherins - blood |
10 |
|
cancer cell |
10 |
|
cancer chemotherapy |
10 |
|
cardiac troponin |
10 |
|
caspase 3 |
10 |
|
chronic hepatitis b |
10 |
|
colonoscopy |
10 |
|
confirmatory factor analysis |
10 |
|
coronavirus - immunology - pathogenicity - physiology |
10 |
|
coronavirus infections - immunology - virology |
10 |
|
cyclin d1 - metabolism |
10 |
|
cyclosporine - therapeutic use |
10 |
|
cytokine and chemokine response |
10 |
|
cytokines - biosynthesis - immunology |
10 |
|
cytokines - genetics - metabolism |
10 |
|
diagnostic imaging |
10 |
|
down-regulation - drug effects |
10 |
|
drug administration schedule |
10 |
|
drug screening |
10 |
|
ebv genome |
10 |
|
endocrinology |
10 |
|
endovascular procedures |
10 |
|
endovascular treatment |
10 |
|
epithelial cells - drug effects - pathology |
10 |
|
esophageal neoplasms - genetics |
10 |
|
exome |
10 |
|
extracellular matrix protein |
10 |
|
extracellular signal-regulated map kinases - metabolism |
10 |
|
fhl2 |
10 |
|
fibroblast growth factor |
10 |
|
fistula |
10 |
|
gastroesophageal reflux |
10 |
|
gene deletion |
10 |
|
genes, p53 - genetics |
10 |
|
genetic testing |
10 |
|
genetics |
10 |
|
germ-line mutation |
10 |
|
glioma |
10 |
|
hepatitis b virus - physiology |
10 |
|
hepatocellular |
10 |
|
hscr |
10 |
|
hypothyroidism |
10 |
|
imaging |
10 |
|
in situ nick-end labeling |
10 |
|
intercellular signaling peptides and proteins - metabolism |
10 |
|
interleukin-6 |
10 |
|
intracellular signaling peptides and proteins |
10 |
|
ischemia-reperfusion injury |
10 |
|
lamivudine |
10 |
|
lipocalin-2 |
10 |
|
liver - drug effects - injuries - metabolism |
10 |
|
liver cell carcinoma |
10 |
|
liver transplantation - methods - statistics and numerical data |
10 |
|
living donors - supply and distribution |
10 |
|
living-donor liver transplantation |
10 |
|
loh |
10 |
|
mapk |
10 |
|
melanoma |
10 |
|
mers-cov |
10 |
|
mice, inbred c57bl |
10 |
|
microcirculation |
10 |
|
milan criteria |
10 |
|
molecular pathology |
10 |
|
neovascularization, pathologic - prevention & control |
10 |
|
new technology |
10 |
|
nf-kappa b - metabolism |
10 |
|
oesophagectomy |
10 |
|
organoid culture |
10 |
|
overexpression |
10 |
|
pathology |
10 |
|
phosphatidylinositol 3-kinases - metabolism |
10 |
|
phosphorylation - drug effects |
10 |
|
plasma |
10 |
|
pneumonia, viral - immunology - virology |
10 |
|
polymorphism, genetic - genetics |
10 |
|
positron-emission tomography |
10 |
|
postoperative period |
10 |
|
protein binding |
10 |
|
protein isoforms |
10 |
|
proto-oncogene proteins c-myc - biosynthesis - genetics |
10 |
|
proto-oncogene proteins c-ret |
10 |
|
proto-oncogene proteins c-ret - genetics |
10 |
|
rare complex disease |
10 |
|
reactive oxygen species |
10 |
|
receptor protein-tyrosine kinases - genetics |
10 |
|
receptors, endothelin - genetics |
10 |
|
reconstruction |
10 |
|
reconstructive surgical procedures - methods |
10 |
|
referral and consultation |
10 |
|
renal transplantation |
10 |
|
reverse transcriptase polymerase chain reaction - methods |
10 |
|
rhoa mutations |
10 |
|
risk prediction |
10 |
|
scarce deceased donors |
10 |
|
sepsis |
10 |
|
sequence homology, amino acid |
10 |
|
signal transduction - drug effects |
10 |
|
signaling |
10 |
|
smell impairment |
10 |
|
sonic hedgehog |
10 |
|
sphingosine - analogs & derivatives |
10 |
|
structure-activity relationship |
10 |
|
surgery medical sciences |
10 |
|
telomerase |
10 |
|
traditional chinese medicine |
10 |
|
trans-activators - genetics - metabolism |
10 |
|
transcriptome sequencing |
10 |
|
transplantation, homologous |
10 |
|
tumor growth |
10 |
|
tumor markers, biological - metabolism |
10 |
|
tumor suppression |
10 |
|
undergraduate |
10 |
|
up-regulation - genetics |
10 |
|
vascular endothelial growth factor a - blood |
10 |
|
vascular endothelial growth factors |
10 |
|
venous infiltration |
10 |
|
viral replication |
10 |
|
virus replication - physiology |
10 |
|
11c-acetate |
9 |
|
adam proteins - biosynthesis - genetics - metabolism |
9 |
|
age-stratified |
9 |
|
airway organoid |
9 |
|
alpha-fetoproteins - analysis |
9 |
|
alternative splicing |
9 |
|
amino acid substitution |
9 |
|
anastomosis, surgical - adverse effects |
9 |
|
antibody therapy |
9 |
|
antigens, cd44 - genetics - metabolism |
9 |
|
asian-specific |
9 |
|
bile |
9 |
|
bilirubin - blood |
9 |
|
bioinformatics |
9 |
|
brca2 |
9 |
|
breath tests |
9 |
|
cancer metabolism |
9 |
|
cancer screening |
9 |
|
carcinoma, hepatocellular - pathology - surgery |
9 |
|
carcinoma, hepatocellular - virology |
9 |
|
cell adhesion molecules |
9 |
|
cell cycle proteins - metabolism |
9 |
|
cell division - drug effects |
9 |
|
chromosomes, human, pair 13 - genetics |
9 |
|
contrast ct |
9 |
|
cost-benefit analysis |
9 |
|
dna, viral - analysis |
9 |
|
drug combinations |
9 |
|
dual specificity phosphatase 6 - genetics - metabolism |
9 |
|
dual-specificity phosphatase 6 (dusp6) |
9 |
|
dyslipidemia |
9 |
|
ebv |
9 |
|
electrophoresis, gel, two-dimensional |
9 |
|
embolization |
9 |
|
endothelial cells - cytology |
9 |
|
epigenesis, genetic |
9 |
|
epithelial cells - pathology |
9 |
|
equipment design |
9 |
|
esophageal neoplasms - blood supply - enzymology - genetics |
9 |
|
esophageal neoplasms - genetics - pathology |
9 |
|
evaluation studies as topic |
9 |
|
exome-chip association analysis |
9 |
|
expression quantitative trait loci |
9 |
|
fact-c |
9 |
|
feasibility studies |
9 |
|
fibroblasts |
9 |
|
fty720 |
9 |
|
gastrectomy |
9 |
|
gastric carcinoma |
9 |
|
gene duplication |
9 |
|
gene knockdown techniques |
9 |
|
genetic markers - genetics |
9 |
|
genome, human |
9 |
|
gpx3 |
9 |
|
graft survival - drug effects |
9 |
|
haplotypes - genetics |
9 |
|
hepatology |
9 |
|
herpesvirus 4, human - genetics |
9 |
|
hif-1α |
9 |
|
hifu |
9 |
|
hipsc-mscs |
9 |
|
hospitals, university |
9 |
|
hsp70 heat-shock proteins - metabolism |
9 |
|
iatrogenic disease |
9 |
|
immunity |
9 |
|
immunoglobulin heavy chains - genetics |
9 |
|
infectivity |
9 |
|
influenza virus |
9 |
|
informed consent |
9 |
|
intracellular signaling peptides and proteins - genetics - metabolism |
9 |
|
intrahepatic cholangiocarcinoma |
9 |
|
invasiveness |
9 |
|
kasai operation |
9 |
|
kasai portoenterostomy |
9 |
|
laparotomy |
9 |
|
ligation |
9 |
|
liver - anatomy & histology |
9 |
|
liver circulation - physiology |
9 |
|
liver diseases - epidemiology |
9 |
|
liver failure - etiology - surgery |
9 |
|
liver failure - surgery |
9 |
|
liver injury |
9 |
|
liver neoplasms - virology |
9 |
|
liver transplantation - mortality |
9 |
|
luciferases - metabolism |
9 |
|
lymph nodes - pathology |
9 |
|
lymphoma, follicular - genetics - pathology |
9 |
|
lymphoma, large b-cell, diffuse - genetics - pathology |
9 |
|
macrophages |
9 |
|
models, animal |
9 |
|
nash |
9 |
|
nasopharyngeal neoplasms - blood supply - enzymology - genetics |
9 |
|
natural selection |
9 |
|
neck |
9 |
|
neoadjuvant chemoradiotherapy |
9 |
|
neoplasm recurrence, local - pathology - surgery |
9 |
|
neoplasm staging - methods |
9 |
|
nitric oxide |
9 |
|
nodal metastasis |
9 |
|
nomogram |
9 |
|
non-invasive treatment |
9 |
|
non-viral liver disease |
9 |
|
oncogene proteins - genetics - metabolism |
9 |
|
palliative care - methods |
9 |
|
pancreatic cancer |
9 |
|
pancreaticoduodenectomy |
9 |
|
pax4 |
9 |
|
postoperative complications - classification - epidemiology |
9 |
|
prediction |
9 |
|
proctology |
9 |
|
proliferating cell nuclear antigen |
9 |
|
propylene glycols - pharmacology |
9 |
|
protein transport |
9 |
|
proteins - metabolism |
9 |
|
proximal differentiation |
9 |
|
radiation |
9 |
|
radioactive iodine |
9 |
|
radiomics |
9 |
|
radiotherapy, adjuvant |
9 |
|
rare variants |
9 |
|
right liver graft |
9 |
|
rna, neoplasm - genetics |
9 |
|
salvage surgery |
9 |
|
screening |
9 |
|
sequence homology, nucleic acid |
9 |
|
sex disparity |
9 |
|
stereotactic body radiation therapy |
9 |
|
stomach neoplasms - genetics - metabolism - pathology |
9 |
|
stroke |
9 |
|
swine |
9 |
|
systemic therapy |
9 |
|
temozolomide |
9 |
|
thyroid nodule |
9 |
|
toxicity |
9 |
|
travel history |
9 |
|
tumor heterogeneity |
9 |
|
tumourigenesis |
9 |
|
ultrasonography, interventional |
9 |
|
venous thromboembolism |
9 |
|
xenograft |
9 |
|
young-onset ischemic stroke |
9 |
|
3d superresolution |
8 |
|
5-fluorouracil |
8 |
|
acetic acid c 11 |
8 |
|
acute pancreatitis |
8 |
|
adenocarcinoma |
8 |
|
adverse events |
8 |
|
aerosolised |
8 |
|
aganglionosis |
8 |
|
age |
8 |
|
alanine transaminase - blood |
8 |
|
anastomosis, surgical - methods |
8 |
|
angiography |
8 |
|
antineoplastic agents, hormonal - therapeutic use |
8 |
|
antiviral agents - adverse effects - therapeutic use |
8 |
|
antiviral therapy |
8 |
|
apoptosis - physiology |
8 |
|
attitude of health personnel |
8 |
|
bile duct |
8 |
|
bile leak |
8 |
|
biliary atresia - complications - surgery |
8 |
|
biliary complications |
8 |
|
bowel function |
8 |
|
brca1 |
8 |
|
burns |
8 |